Wiser Wealth Management Inc Takes Position in Eli Lilly and Company (NYSE:LLY)

Wiser Wealth Management Inc bought a new position in shares of Eli Lilly and Company (NYSE:LLY) in the third quarter, HoldingsChannel reports. The firm bought 563 shares of the company’s stock, valued at approximately $499,000.

A number of other hedge funds also recently bought and sold shares of the business. Vanguard Group Inc. grew its position in shares of Eli Lilly and Company by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 72,745,011 shares of the company’s stock worth $56,592,709,000 after buying an additional 1,133,810 shares during the last quarter. Capital Research Global Investors grew its stake in Eli Lilly and Company by 6.0% in the first quarter. Capital Research Global Investors now owns 8,031,531 shares of the company’s stock worth $6,248,210,000 after purchasing an additional 453,939 shares during the period. Capital International Investors raised its holdings in Eli Lilly and Company by 5.1% in the first quarter. Capital International Investors now owns 6,972,393 shares of the company’s stock worth $5,424,243,000 after purchasing an additional 335,560 shares in the last quarter. Fisher Asset Management LLC lifted its position in Eli Lilly and Company by 1.9% during the fourth quarter. Fisher Asset Management LLC now owns 4,542,089 shares of the company’s stock valued at $2,647,675,000 after buying an additional 85,015 shares during the period. Finally, GQG Partners LLC boosted its holdings in shares of Eli Lilly and Company by 20.2% during the 1st quarter. GQG Partners LLC now owns 3,848,886 shares of the company’s stock valued at $2,994,280,000 after buying an additional 648,094 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Activity

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 93,593 shares of the company’s stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $918.64, for a total value of $85,978,273.52. Following the completion of the sale, the insider now owns 97,153,810 shares in the company, valued at $89,249,376,018.40. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of LLY opened at $885.15 on Friday. The firm has a fifty day simple moving average of $898.50 and a two-hundred day simple moving average of $846.49. The firm has a market cap of $841.25 billion, a PE ratio of 130.36, a P/E/G ratio of 2.78 and a beta of 0.42. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a 1-year low of $523.63 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The company had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. On average, equities analysts anticipate that Eli Lilly and Company will post 16.49 EPS for the current year.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of recent research reports. Jefferies Financial Group lifted their price target on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research report on Monday, June 24th. Wells Fargo & Company boosted their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research report on Friday, August 9th. Morgan Stanley restated an “overweight” rating and issued a $1,106.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Bank of America boosted their target price on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, Citigroup started coverage on Eli Lilly and Company in a research note on Friday, September 13th. They issued a “buy” rating and a $1,060.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $977.35.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.